Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
AuthorSchettini, F; Sobhani, N; Ianza, A; Triulzi, T; Molteni, A; Lazzari, MC; Strina, C; Milani, M; Corona, SP; Sirico, M; ...
Source TitleBreast Cancer Research and Treatment
AffiliationSir Peter MacCallum Department of Oncology
Document TypeJournal Article
CitationsSchettini, F., Sobhani, N., Ianza, A., Triulzi, T., Molteni, A., Lazzari, M. C., Strina, C., Milani, M., Corona, S. P., Sirico, M., Bernocchi, O., Giudici, F., Cappelletti, M. R., Ciruelos, E., Jerusalem, G., Loi, S., Fox, S. B. & Generali, D. (2020). Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. BREAST CANCER RESEARCH AND TREATMENT, 184 (2), pp.421-431. https://doi.org/10.1007/s10549-020-05856-3.
Access StatusOpen Access
PURPOSE: mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the association between treatment-associated immune system features and everolimus activity. METHODS: We retrospectively explored a correlation with the therapeutic activity of everolimus and tumor-associated immune pathways with ingenuity pathway analysis (IPA), neutrophil-to-lymphocyte ratio (NLR), circulating lymphocytes, and endothelial cells (CECs) in 3 different HR+ mBC studies, including the BALLET phase IIIb study. RESULTS: The circulating levels of CD3+/CD8+, CD3+/CD4+, and overall T lymphocytes were higher in responders versus non-responders at baseline (p = 0.017, p < 0.001, p = 0.034) and after treatment (p = 0.01, p = 0.003, p = 0.023). Reduced CECs, a tumor neoangiogenesis marker, were observed in responders after treatment (p < 0.001). Patients with low NLR (≤ 4.4) showed a better progression-free survival compared to patients with high NLR (> 4.4) (p = 0.01). IPA showed that the majority of immunity-related genes were found upregulated in responders compared to non-responders before treatment, but not after. CONCLUSIONS: Lymphocytes subpopulations, CECs and NLR could be interesting biomarkers predictive of response to everolimus-based regimens, potentially useful in daily clinical practice to select/monitor everolimus-based treatment in mBC. Further studies to confirm such hypotheses are warranted.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References